This is a routine, pre-planned insider sale under a 10b5-1 plan. The small size and pre-arranged nature suggest no negative signal. Monitor for any acceleration of insider selling or unexpected Form 4 filings that could indicate a change in sentiment.
Price Chart
Executive Summary
BridgeBio Pharma director Randal Scott filed a Form 144 notice of intent to sell 2,196 shares of common stock, with an estimated aggregate market value of approximately $150,711. The shares were acquired via restricted stock units that vested on June 20, 2026. The sale is being conducted under a Rule 10b5-1 trading plan established on June 27, 2025, which mitigates concerns about opportunistic timing. The proposed sale represents a de minimis portion of Scott's holdings relative to the company's $13.6B market cap and is consistent with routine insider diversification.
Key Facts
- Director Randal Scott filed Form 144 to sell 2,196 shares of BBIO common stock.
- Estimated aggregate market value of the proposed sale is approximately $150,711.
- Shares were acquired through restricted stock units that vested on June 20, 2026.
- Sale is being executed under a Rule 10b5-1 trading plan dated June 27, 2025.
- The proposed sale represents less than 0.001% of BBIO's $13.6B market capitalization.
- Recent insider activity (30d) shows 3 sells totaling $2.9M, indicating ongoing but modest insider selling.
Financial Impact
Proposed sale of 2,196 shares valued at ~$150,711 — immaterial relative to $13.6B market cap.
Risk Factors
- Insider selling pattern could accelerate if additional Form 144s or Form 4s are filed by other executives.
- The 10b5-1 plan was established nearly a year ago, so the sale is not reactive to current fundamentals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006457 |
| Document: 0001950047-26-006457-index.html | 0001950047-26-006457 |
| Document: 0001950047-26-006457.txt | 0001950047-26-006457 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access